Immunohistochemical differential diagnosis between urothelial carcinoma and prostate adenocarcinoma among Egyptian patients

Sakr, Saber A.; Abdelwahed, Moshera M.; El-Sahra, Doaa Galal

doi:10.1016/j.biopha.2014.08.003

Cited by 5 publications

(4 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our series, 93% of documented PC and 97% of documented UC expressed a diagnostic immunohistochemical profile (PC: PSA+/HMWCK− vs UC: PSA−/HMWCK+) and this was similar to Sakr et al. study.…”

Section: Discussionsupporting

confidence: 91%

Do HOXB13 and P63 have a role in differentiating poorly differentiated prostatic carcinoma from urothelial high‐grade carcinoma?

Alshenawy

Saied

2015

APMIS

View full text Add to dashboard Cite

Poorly differentiated prostatic carcinoma may overlap with high-grade urothelial carcinoma; a distinction is a must as treatments differ. This study aims to evaluate traditional (PSA and HMWCK) and relatively novel (P63 and HOXB13) markers in distinguishing them; and to evaluate their role in the diagnosis of challenging cases. Sections from: diagnosed group includes 65 prostatic and urothelial carcinoma cases were stained with PSA, HMWCK, P63, and HOXB13. Sensitivity, specificity, and accuracy were evaluated. The second group includes 25 challenging cases which were stained first by PSA and HMWCK, then solved the problematic cases with P63 and HOXB13. PSA and HMWCK were sensitive and specific for prostatic and urothelial carcinomas, respectively, but the sensitivity and accuracy were higher for P63 and HOXB13. By using the traditional markers, 17 cases were diagnosed in the second group while the remaining eight cases need the novel markers to be diagnosed. A confident diagnosis can be established in the majority of cases of poorly differentiated carcinoma in either prostatic or urothelial by using a panel of PSA and HMWCK. In some problematic cases, an extended panel including P63 and HOXB13 is helpful in resolving the diagnosis.

show abstract

Section: Discussionsupporting

confidence: 91%

Do HOXB13 and P63 have a role in differentiating poorly differentiated prostatic carcinoma from urothelial high‐grade carcinoma?

Alshenawy

Saied

2015

APMIS

View full text Add to dashboard Cite

show abstract

“…In the study by Sakr et al, 102 CK10 was negative in all UC cases and positive in 52.4% cases of PC. Similar results were obtained by Fillies et al 103…”

Section: Immunohistochemistrymentioning

confidence: 84%

“…Such distinction is not often feasible on morphological grounds alone, and panels of antibodies have been proposed that may support a correct diagnosis. 24,34,35,38,46,53,54,66,75,78,80,82,102,144-146 In this review, we summarize these suggestions, highlight the potential issues in using single antibodies, and finally discuss some less frequent, yet intriguing differential diagnoses among tumors arising in the bladder and prostate.…”

Section: Resultsmentioning

confidence: 99%

Morphological and Immunohistochemical Biomarkers in Distinguishing Prostate Carcinoma and Urothelial Carcinoma: A Comprehensive Review

et al. 2018

View full text Add to dashboard Cite

The differential diagnosis between high-grade prostate carcinoma and infiltrating urothelial carcinoma (UC) in transurethral resection prostate specimens as well as cystoprostatectomy specimens may often be challenging due to morphologic and clinical overlap of the 2 entities. Such distinction has critical therapeutic and staging consequences, yet it is hampered by both issues in morphology and by the low accuracy rates of single immunohistochemical markers, as reported in literature. This review aims to provide a comprehensive analysis of the available morphological and immunohistochemical parameters, which may allow to discriminate between prostate carcinoma and urothelial carcinoma in the proper clinical context and to discuss their diagnostic applications in daily practice.

show abstract

“…Therefore, IHC analysis was the foundational method for the pathological diagnosis of mediastinal masses in this case. IHC staining for p63 and CK7 helps distinguish adenocarcinoma of the prostate from UC of the bladder ( 38 ). Notably, the expression of CK7 is found in 100% of transitional cell carcinomas ( 39 ).…”

Section: Discussionmentioning

confidence: 99%

Occult urothelial carcinoma with mediastinal metastasis: A case report

Zheng,

Peng,

et al. 2024

Oncol Lett

View full text Add to dashboard Cite

Occult urothelial carcinoma (UC), particularly with mediastinal metastases, is an uncommon clinical occurrence. The present study describes the unusual case of a 70-year-old male patient who developed mediastinal metastases from an occult UC. Histological evaluations and immunohistochemical features of the mediastinal tumor were indicative of UC; however, extensive imaging failed to identify the primary urological lesion. The findings suggest that mediastinal metastases from UCs, despite their rarity, should be considered in cases where patients with mediastinal tumors exhibit chest-related symptoms. Prompt pathological examinations are crucial for ascertaining the nature and origin of the tumor. Moreover, individualized treatment should be performed in strict accordance with the established oncology guidelines.

show abstract

Immunohistochemical differential diagnosis between urothelial carcinoma and prostate adenocarcinoma among Egyptian patients

Cited by 5 publications

References 26 publications

Do HOXB13 and P63 have a role in differentiating poorly differentiated prostatic carcinoma from urothelial high‐grade carcinoma?

Do HOXB13 and P63 have a role in differentiating poorly differentiated prostatic carcinoma from urothelial high‐grade carcinoma?

Morphological and Immunohistochemical Biomarkers in Distinguishing Prostate Carcinoma and Urothelial Carcinoma: A Comprehensive Review

Occult urothelial carcinoma with mediastinal metastasis: A case report

Contact Info

Product

Resources

About